nodes	percent_of_prediction	percent_of_DWPC	metapath
Cyclophosphamide—Dry cough—Hydrochlorothiazide—nephrolithiasis	0.0933	0.11	CcSEcCtD
Cyclophosphamide—Arrhythmia supraventricular—Hydrochlorothiazide—nephrolithiasis	0.0372	0.0438	CcSEcCtD
Cyclophosphamide—Respiratory distress—Hydrochlorothiazide—nephrolithiasis	0.0227	0.0267	CcSEcCtD
Cyclophosphamide—CYP2C19—urine—nephrolithiasis	0.0226	0.15	CbGeAlD
Cyclophosphamide—Encephalopathy—Hydrochlorothiazide—nephrolithiasis	0.0225	0.0265	CcSEcCtD
Cyclophosphamide—Ventricular arrhythmia—Hydrochlorothiazide—nephrolithiasis	0.0195	0.0229	CcSEcCtD
Cyclophosphamide—Ventricular fibrillation—Hydrochlorothiazide—nephrolithiasis	0.0188	0.0222	CcSEcCtD
Cyclophosphamide—CYP2C9—urine—nephrolithiasis	0.0175	0.117	CbGeAlD
Cyclophosphamide—Rhabdomyolysis—Hydrochlorothiazide—nephrolithiasis	0.0163	0.0192	CcSEcCtD
Cyclophosphamide—Hyperuricaemia—Hydrochlorothiazide—nephrolithiasis	0.0156	0.0183	CcSEcCtD
Cyclophosphamide—Vasculitis—Hydrochlorothiazide—nephrolithiasis	0.0148	0.0174	CcSEcCtD
Cyclophosphamide—Blood uric acid increased—Hydrochlorothiazide—nephrolithiasis	0.0147	0.0173	CcSEcCtD
Cyclophosphamide—Ventricular tachycardia—Hydrochlorothiazide—nephrolithiasis	0.0144	0.017	CcSEcCtD
Cyclophosphamide—Hyperkalaemia—Hydrochlorothiazide—nephrolithiasis	0.0142	0.0167	CcSEcCtD
Cyclophosphamide—CYP3A4—urine—nephrolithiasis	0.0133	0.0889	CbGeAlD
Cyclophosphamide—CYP2D6—urine—nephrolithiasis	0.0131	0.0874	CbGeAlD
Cyclophosphamide—Pulmonary oedema—Hydrochlorothiazide—nephrolithiasis	0.0128	0.0151	CcSEcCtD
Cyclophosphamide—Diabetes mellitus—Hydrochlorothiazide—nephrolithiasis	0.012	0.0142	CcSEcCtD
Cyclophosphamide—Polyuria—Hydrochlorothiazide—nephrolithiasis	0.0119	0.014	CcSEcCtD
Cyclophosphamide—Swelling—Hydrochlorothiazide—nephrolithiasis	0.0119	0.014	CcSEcCtD
Cyclophosphamide—Gastroenteritis—Hydrochlorothiazide—nephrolithiasis	0.0118	0.0139	CcSEcCtD
Cyclophosphamide—Haemolytic anaemia—Hydrochlorothiazide—nephrolithiasis	0.0116	0.0137	CcSEcCtD
Cyclophosphamide—CYP3A7-CYP3A51P—nephron tubule—nephrolithiasis	0.0116	0.077	CbGeAlD
Cyclophosphamide—Nasal congestion—Hydrochlorothiazide—nephrolithiasis	0.0115	0.0135	CcSEcCtD
Cyclophosphamide—Hot flush—Hydrochlorothiazide—nephrolithiasis	0.0112	0.0132	CcSEcCtD
Cyclophosphamide—Menopausal symptoms—Hydrochlorothiazide—nephrolithiasis	0.0111	0.0131	CcSEcCtD
Cyclophosphamide—Atrial fibrillation—Hydrochlorothiazide—nephrolithiasis	0.0111	0.013	CcSEcCtD
Cyclophosphamide—Renal impairment—Hydrochlorothiazide—nephrolithiasis	0.011	0.013	CcSEcCtD
Cyclophosphamide—Hyponatraemia—Hydrochlorothiazide—nephrolithiasis	0.0105	0.0124	CcSEcCtD
Cyclophosphamide—Gastrointestinal haemorrhage—Hydrochlorothiazide—nephrolithiasis	0.0105	0.0123	CcSEcCtD
Cyclophosphamide—CYP3A7-CYP3A51P—cortex of kidney—nephrolithiasis	0.00989	0.0659	CbGeAlD
Cyclophosphamide—Toxic epidermal necrolysis—Hydrochlorothiazide—nephrolithiasis	0.00943	0.0111	CcSEcCtD
Cyclophosphamide—Weight increased—Hydrochlorothiazide—nephrolithiasis	0.00824	0.0097	CcSEcCtD
Cyclophosphamide—Hyperglycaemia—Hydrochlorothiazide—nephrolithiasis	0.00817	0.00961	CcSEcCtD
Cyclophosphamide—Pneumonia—Hydrochlorothiazide—nephrolithiasis	0.00812	0.00955	CcSEcCtD
Cyclophosphamide—Stevens-Johnson syndrome—Hydrochlorothiazide—nephrolithiasis	0.008	0.00942	CcSEcCtD
Cyclophosphamide—Acute coronary syndrome—Hydrochlorothiazide—nephrolithiasis	0.00796	0.00936	CcSEcCtD
Cyclophosphamide—Renal failure—Hydrochlorothiazide—nephrolithiasis	0.00794	0.00934	CcSEcCtD
Cyclophosphamide—Myocardial infarction—Hydrochlorothiazide—nephrolithiasis	0.00791	0.00931	CcSEcCtD
Cyclophosphamide—Neuropathy peripheral—Hydrochlorothiazide—nephrolithiasis	0.00791	0.00931	CcSEcCtD
Cyclophosphamide—Jaundice—Hydrochlorothiazide—nephrolithiasis	0.00787	0.00926	CcSEcCtD
Cyclophosphamide—Conjunctivitis—Hydrochlorothiazide—nephrolithiasis	0.00785	0.00923	CcSEcCtD
Cyclophosphamide—Sweating—Hydrochlorothiazide—nephrolithiasis	0.00774	0.00911	CcSEcCtD
Cyclophosphamide—Haematuria—Hydrochlorothiazide—nephrolithiasis	0.0077	0.00906	CcSEcCtD
Cyclophosphamide—Agranulocytosis—Hydrochlorothiazide—nephrolithiasis	0.00753	0.00886	CcSEcCtD
Cyclophosphamide—Bradycardia—Hydrochlorothiazide—nephrolithiasis	0.00738	0.00868	CcSEcCtD
Cyclophosphamide—Rhinitis—Hydrochlorothiazide—nephrolithiasis	0.00727	0.00855	CcSEcCtD
Cyclophosphamide—Hepatitis—Hydrochlorothiazide—nephrolithiasis	0.00725	0.00853	CcSEcCtD
Cyclophosphamide—Hypoaesthesia—Hydrochlorothiazide—nephrolithiasis	0.00721	0.00848	CcSEcCtD
Cyclophosphamide—Visual impairment—Hydrochlorothiazide—nephrolithiasis	0.00698	0.00822	CcSEcCtD
Cyclophosphamide—Erythema multiforme—Hydrochlorothiazide—nephrolithiasis	0.00685	0.00806	CcSEcCtD
Cyclophosphamide—Tinnitus—Hydrochlorothiazide—nephrolithiasis	0.00676	0.00795	CcSEcCtD
Cyclophosphamide—Flushing—Hydrochlorothiazide—nephrolithiasis	0.00673	0.00791	CcSEcCtD
Cyclophosphamide—Arrhythmia—Hydrochlorothiazide—nephrolithiasis	0.00647	0.00762	CcSEcCtD
Cyclophosphamide—Alopecia—Hydrochlorothiazide—nephrolithiasis	0.0064	0.00754	CcSEcCtD
Cyclophosphamide—Erythema—Hydrochlorothiazide—nephrolithiasis	0.00631	0.00742	CcSEcCtD
Cyclophosphamide—Dysgeusia—Hydrochlorothiazide—nephrolithiasis	0.00618	0.00727	CcSEcCtD
Cyclophosphamide—Muscle spasms—Hydrochlorothiazide—nephrolithiasis	0.00607	0.00714	CcSEcCtD
Cyclophosphamide—Vision blurred—Hydrochlorothiazide—nephrolithiasis	0.00595	0.007	CcSEcCtD
Cyclophosphamide—Tremor—Hydrochlorothiazide—nephrolithiasis	0.00591	0.00695	CcSEcCtD
Cyclophosphamide—Ill-defined disorder—Hydrochlorothiazide—nephrolithiasis	0.00585	0.00689	CcSEcCtD
Cyclophosphamide—Anaemia—Hydrochlorothiazide—nephrolithiasis	0.00583	0.00686	CcSEcCtD
Cyclophosphamide—Agitation—Hydrochlorothiazide—nephrolithiasis	0.0058	0.00682	CcSEcCtD
Cyclophosphamide—Malaise—Hydrochlorothiazide—nephrolithiasis	0.00569	0.00669	CcSEcCtD
Cyclophosphamide—Leukopenia—Hydrochlorothiazide—nephrolithiasis	0.00565	0.00664	CcSEcCtD
Cyclophosphamide—Palpitations—Hydrochlorothiazide—nephrolithiasis	0.00558	0.00656	CcSEcCtD
Cyclophosphamide—Cough—Hydrochlorothiazide—nephrolithiasis	0.00551	0.00648	CcSEcCtD
Cyclophosphamide—Myalgia—Hydrochlorothiazide—nephrolithiasis	0.00537	0.00632	CcSEcCtD
Cyclophosphamide—Arthralgia—Hydrochlorothiazide—nephrolithiasis	0.00537	0.00632	CcSEcCtD
Cyclophosphamide—Chest pain—Hydrochlorothiazide—nephrolithiasis	0.00537	0.00632	CcSEcCtD
Cyclophosphamide—Discomfort—Hydrochlorothiazide—nephrolithiasis	0.00531	0.00624	CcSEcCtD
Cyclophosphamide—Confusional state—Hydrochlorothiazide—nephrolithiasis	0.00519	0.00611	CcSEcCtD
Cyclophosphamide—Anaphylactic shock—Hydrochlorothiazide—nephrolithiasis	0.00515	0.00606	CcSEcCtD
Cyclophosphamide—Oedema—Hydrochlorothiazide—nephrolithiasis	0.00515	0.00606	CcSEcCtD
Cyclophosphamide—Shock—Hydrochlorothiazide—nephrolithiasis	0.00507	0.00596	CcSEcCtD
Cyclophosphamide—Thrombocytopenia—Hydrochlorothiazide—nephrolithiasis	0.00504	0.00593	CcSEcCtD
Cyclophosphamide—Tachycardia—Hydrochlorothiazide—nephrolithiasis	0.00503	0.00591	CcSEcCtD
Cyclophosphamide—Hyperhidrosis—Hydrochlorothiazide—nephrolithiasis	0.00498	0.00586	CcSEcCtD
Cyclophosphamide—Anorexia—Hydrochlorothiazide—nephrolithiasis	0.00491	0.00577	CcSEcCtD
Cyclophosphamide—CYP2C8—renal system—nephrolithiasis	0.00482	0.0321	CbGeAlD
Cyclophosphamide—Hypotension—Hydrochlorothiazide—nephrolithiasis	0.00481	0.00566	CcSEcCtD
Cyclophosphamide—CYP3A5—nephron tubule—nephrolithiasis	0.00478	0.0319	CbGeAlD
Cyclophosphamide—CYP2B6—nephron tubule—nephrolithiasis	0.00475	0.0317	CbGeAlD
Cyclophosphamide—Musculoskeletal discomfort—Hydrochlorothiazide—nephrolithiasis	0.00469	0.00552	CcSEcCtD
Cyclophosphamide—CYP2C8—kidney—nephrolithiasis	0.00466	0.031	CbGeAlD
Cyclophosphamide—Paraesthesia—Hydrochlorothiazide—nephrolithiasis	0.00462	0.00544	CcSEcCtD
Cyclophosphamide—Dyspnoea—Hydrochlorothiazide—nephrolithiasis	0.00459	0.0054	CcSEcCtD
Cyclophosphamide—Decreased appetite—Hydrochlorothiazide—nephrolithiasis	0.00448	0.00527	CcSEcCtD
Cyclophosphamide—Fatigue—Hydrochlorothiazide—nephrolithiasis	0.00444	0.00522	CcSEcCtD
Cyclophosphamide—Pain—Hydrochlorothiazide—nephrolithiasis	0.0044	0.00518	CcSEcCtD
Cyclophosphamide—Constipation—Hydrochlorothiazide—nephrolithiasis	0.0044	0.00518	CcSEcCtD
Cyclophosphamide—CYP3A5—renal system—nephrolithiasis	0.00435	0.029	CbGeAlD
Cyclophosphamide—CYP2B6—renal system—nephrolithiasis	0.00432	0.0288	CbGeAlD
Cyclophosphamide—Feeling abnormal—Hydrochlorothiazide—nephrolithiasis	0.00424	0.00499	CcSEcCtD
Cyclophosphamide—CYP3A5—kidney—nephrolithiasis	0.0042	0.028	CbGeAlD
Cyclophosphamide—CYP2B6—kidney—nephrolithiasis	0.00418	0.0278	CbGeAlD
Cyclophosphamide—CYP3A5—cortex of kidney—nephrolithiasis	0.00409	0.0273	CbGeAlD
Cyclophosphamide—Urticaria—Hydrochlorothiazide—nephrolithiasis	0.00409	0.00481	CcSEcCtD
Cyclophosphamide—Body temperature increased—Hydrochlorothiazide—nephrolithiasis	0.00407	0.00479	CcSEcCtD
Cyclophosphamide—Hypersensitivity—Hydrochlorothiazide—nephrolithiasis	0.00379	0.00446	CcSEcCtD
Cyclophosphamide—Asthenia—Hydrochlorothiazide—nephrolithiasis	0.00369	0.00435	CcSEcCtD
Cyclophosphamide—Pruritus—Hydrochlorothiazide—nephrolithiasis	0.00364	0.00429	CcSEcCtD
Cyclophosphamide—Diarrhoea—Hydrochlorothiazide—nephrolithiasis	0.00352	0.00415	CcSEcCtD
Cyclophosphamide—Dizziness—Hydrochlorothiazide—nephrolithiasis	0.0034	0.00401	CcSEcCtD
Cyclophosphamide—Vomiting—Hydrochlorothiazide—nephrolithiasis	0.00327	0.00385	CcSEcCtD
Cyclophosphamide—CYP3A4—renal system—nephrolithiasis	0.00326	0.0217	CbGeAlD
Cyclophosphamide—Rash—Hydrochlorothiazide—nephrolithiasis	0.00325	0.00382	CcSEcCtD
Cyclophosphamide—Dermatitis—Hydrochlorothiazide—nephrolithiasis	0.00324	0.00382	CcSEcCtD
Cyclophosphamide—Headache—Hydrochlorothiazide—nephrolithiasis	0.00323	0.0038	CcSEcCtD
Cyclophosphamide—CYP2D6—renal system—nephrolithiasis	0.00321	0.0214	CbGeAlD
Cyclophosphamide—CYP3A4—kidney—nephrolithiasis	0.00316	0.021	CbGeAlD
Cyclophosphamide—CYP2D6—kidney—nephrolithiasis	0.0031	0.0207	CbGeAlD
Cyclophosphamide—Nausea—Hydrochlorothiazide—nephrolithiasis	0.00306	0.0036	CcSEcCtD
Cyclophosphamide—ABCB1—nephron tubule—nephrolithiasis	0.00254	0.0169	CbGeAlD
Cyclophosphamide—ABCB1—renal system—nephrolithiasis	0.00231	0.0154	CbGeAlD
Cyclophosphamide—ABCB1—kidney—nephrolithiasis	0.00223	0.0149	CbGeAlD
Cyclophosphamide—ABCB1—cortex of kidney—nephrolithiasis	0.00218	0.0145	CbGeAlD
